Effect of Valerian on The Quality of Sleep and Anxiety in Patients with MS
- Conditions
- MS.Demyelinating diseases of the central nervous systemG35-G37
- Registration Number
- IRCT2017070531348N2
- Lead Sponsor
- niversity Of Social Welfare And Rehabilitation Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 46
Entry Criteria: Confirmation of MS by the center's neurologist; The absence of other neurological disorders and mental and mental disorders, according to the patient's case and opinion; At least six months of diagnosis; Having reading and writing skills or having a companion to complete; the person questionnaire in the age range of 20-45 years; Failure to have liver disease or deficiency in liver enzymes, lack of pregnancy and lactation; Failure to receive complementary and alternative therapies during the past three months. (To reduce anxiety and improve sleep quality.)
Exit criteria: No patient incentive to continue cooperation. During the research; To perform this intervention in the past (because of the decrease in the amount of suppression, the probability of answering the questions based on the information stored in the previous study); Not having enough insight into the disease and not having the ability to collaborate in the study; Drug use New sedative and hypnotic; Alcohol users, Barbiturates and Benzodiazepine (in iron users between consumption Valerie N and iron should be 1 to 2 hours apart); Hepatitis and pregnancy ; If not used for 2 days
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sleep Quality, Anxiety. Timepoint: Befor Intervention- After Intervention. Method of measurement: Questionnaire.
- Secondary Outcome Measures
Name Time Method Improve The Quality of Sleep, Reduce Anxiety. Timepoint: Before The Intervention - After The End of Intervention. Method of measurement: Questionnaire.